The efficacy and pharmacokinetics of brincidofovir for the treatment of lethal rabbitpox virus infection: a model of smallpox disease.

[1]  H. Golding,et al.  Postchallenge Administration of Brincidofovir Protects Healthy and Immune-Deficient Mice Reconstituted with Limited Numbers of T Cells from Lethal Challenge with IHD-J-Luc Vaccinia Virus , 2015, Journal of Virology.

[2]  R. Buller,et al.  Co-administration of the broad-spectrum antiviral, brincidofovir (CMX001), with smallpox vaccine does not compromise vaccine protection in mice challenged with ectromelia virus , 2014, Antiviral research.

[3]  G. Papanicolaou,et al.  CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. , 2013, The New England journal of medicine.

[4]  G. Painter,et al.  First Pharmacokinetic and Safety Study in Humans of the Novel Lipid Antiviral Conjugate CMX001, a Broad-Spectrum Oral Drug Active against Double-Stranded DNA Viruses , 2012, Antimicrobial Agents and Chemotherapy.

[5]  J. Sagartz,et al.  Evaluation of disease and viral biomarkers as triggers for therapeutic intervention in respiratory mousepox – An animal model of smallpox , 2012, Antiviral research.

[6]  C. Fletcher,et al.  Plasma and Intracellular Population Pharmacokinetic Analysis of Tenofovir in HIV-1-Infected Patients , 2011, Antimicrobial Agents and Chemotherapy.

[7]  A. Rice,et al.  Efficacy of CMX001 as a Prophylactic and Presymptomatic Antiviral Agent in New Zealand White Rabbits Infected with Rabbitpox Virus, a Model for Orthopoxvirus Infections of Humans , 2011, Viruses.

[8]  A. Rice,et al.  Efficacy of CMX001 as a Post Exposure Antiviral in New Zealand White Rabbits Infected with Rabbitpox Virus, a Model for Orthopoxvirus Infections of Humans , 2011, Viruses.

[9]  G. Painter,et al.  Development of CMX001 for the Treatment of Poxvirus Infections , 2010, Viruses.

[10]  A. Siddiqui,et al.  Ectromelia Virus Infections of Mice as a Model to Support the Licensure of Anti-Orthopoxvirus Therapeutics , 2010, Viruses.

[11]  A. Siddiqui,et al.  Mousepox in the C57BL/6 strain provides an improved model for evaluating anti-poxvirus therapies , 2008, Virology.

[12]  R. Buller,et al.  Efficacy of therapeutic intervention with an oral ether–lipid analogue of cidofovir (CMX001) in a lethal mousepox model , 2007, Antiviral research.

[13]  R. Moyer,et al.  Rabbitpox Virus and Vaccinia Virus Infection of Rabbits as a Model for Human Smallpox , 2007, Journal of Virology.

[14]  B. Kearney,et al.  Intracellular Pharmacokinetics of Tenofovir Diphosphate, Carbovir Triphosphate, and Lamivudine Triphosphate in Patients Receiving Triple-Nucleoside Regimens , 2005, Journal of acquired immune deficiency syndromes.

[15]  K. Hostetler,et al.  Oral Treatment of Cowpox and Vaccinia Virus Infections in Mice with Ether Lipid Esters of Cidofovir , 2004, Antimicrobial Agents and Chemotherapy.

[16]  D. Norwood,et al.  Smallpox and pan-Orthopox Virus Detection by Real-Time 3′-Minor Groove Binder TaqMan Assays on the Roche LightCycler and the Cepheid Smart Cycler Platforms , 2004, Journal of Clinical Microbiology.

[17]  R. Buller,et al.  Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. , 2004, Virology.

[18]  Stuart L. Beal,et al.  Ways to Fit a PK Model with Some Data Below the Quantification Limit , 2001, Journal of Pharmacokinetics and Pharmacodynamics.